Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. Genmab A/S has moved -37.4% over the last year ...

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees ...

Genmab A/S (Nasdaq: GMAB) announced today that AbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Shares of Genmab (NASDAQ:GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc (NYSE:ABBV). AbbVie ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...